TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30184513

Group type: EXPERIMENTAL
Intervention: Serum 25-hydroxyvitamin D levels <10.0 ng/mL
Number of subjects: 785

Group type: EXPERIMENTAL
Intervention: Higher serum 25-hydroxyvitamin D levels
Number of subjects: 785

Group type: EXPERIMENTAL
Intervention: Having T allele of Fok1
Number of subjects: 785

Group type: EXPERIMENTAL
Intervention: Having bb genotype of Bsm1
Number of subjects: 785

Group type: EXPERIMENTAL
Intervention: Interaction between 25(OH)D and VDR gene polymorphisms (Fok1)
Number of subjects: 785

Group type: EXPERIMENTAL
Intervention: Interaction between 25(OH)D and VDR gene polymorphisms (Bsm1)
Number of subjects: 785
Study: 28891788

Group type: EXPERIMENTAL
Intervention: Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF (EVG/COBI/FTC/TDF)
Number of subjects: 575

Group type: COMPARATOR
Intervention: Atazanavir + Ritonavir + Emtricitabine/Tenofovir DF (ATV + RTV + FTC/TDF)
Number of subjects: 575

Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 575
Study: 25732786

Group type: EXPERIMENTAL
Intervention: A‐tDCS over the left inferior frontal gyrus (IFG)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham condition
Number of subjects: 20
Study: 23827399

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) for patients with previous CABG
Number of subjects: 919

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) for patients with previous CABG with ≥1 saphenous vein graft intervention
Number of subjects: 919

Group type: COMPARATOR
Intervention: Patients without previous CABG
Number of subjects: 919
Study: 21115795

Group type: EXPERIMENTAL
Intervention: 200 mg oral torezolid phosphate once daily for 5 to 7 days
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: 300 mg oral torezolid phosphate once daily for 5 to 7 days
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: 400 mg oral torezolid phosphate once daily for 5 to 7 days
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Overall (all doses) for patients with S. aureus isolated at baseline
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Overall (all doses) for patients with MRSA isolated at baseline
Number of subjects: 188
Study: 19067789

Group type: EXPERIMENTAL
Intervention: Erectile Dysfunction (ED)
Number of subjects: 3810
Study: 17323107

Group type: EXPERIMENTAL
Intervention: Fractured leg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control leg
Number of subjects: 60
Study: 15127203

Group type: EXPERIMENTAL
Intervention: Intensive, individualised diet and exercise
Number of subjects: 490

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 490
Study: 11436945

Group type: EXPERIMENTAL
Intervention: Intracameral epinephrine 1:25,000
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intracameral epinephrine 1:50,000
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intracameral epinephrine 1:100,000
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intracameral epinephrine 1:200,000
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intracameral epinephrine 1:400,000
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: All concentrations of epinephrine
Number of subjects: 60
Study: 9878937

Group type: EXPERIMENTAL
Intervention: Weight-adjusted heparin dosing
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Point-of-care coagulation monitoring
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Weight-adjusted heparin dosing and point-of-care monitoring
Number of subjects: 113
Study: 7608391

Group type: EXPERIMENTAL
Intervention: Multicomponent maskers (2-100 sinusoids) presented at 60 dB SPL
Number of subjects: 49

Group type: COMPARATOR
Intervention: Broadband noise masker
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Lowering masker uncertainty (frequencies randomized between but not within trials)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Training effects within experiment
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Longer testing for five listeners
Number of subjects: 49
Study: 2104626

Group type: COMPARATOR
Intervention: Testosterone enanthate (50 mg/week)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Testosterone enanthate (100 mg/week)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Testosterone enanthate (300 mg/week)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo (sesame oil, 1 mL)
Number of subjects: 51
Study: 102615

Group type: EXPERIMENTAL
Intervention: Oral and parenteral antibiotics with extensive bowel preparation in colorectal surgery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cefazolin, gentamycin, and rifamycin in biliary surgery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Early preoperative administration of penicillinase-resistant drugs in open fractures (second and third degree lesions)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: No prophylaxis in first degree injuries
Number of subjects: 0
Study: 31880734

Group type: EXPERIMENTAL
Intervention: Indoor exercise on higher air pollution days
Number of subjects: 18

Group type: COMPARATOR
Intervention: Outdoor exercise
Number of subjects: 18
Study: 31280096

Group type: EXPERIMENTAL
Intervention: No caregiver for dependants with difficulties in IADL
Number of subjects: 2006

Group type: EXPERIMENTAL
Intervention: Difficulties in ADL
Number of subjects: 2006

Group type: EXPERIMENTAL
Intervention: Cardiac and cerebrovascular pathologies, smoking, and drinking
Number of subjects: 2006

Group type: EXPERIMENTAL
Intervention: Subjective health, grip power, cognition score, depression, cardiac and cerebrovascular diseases, number of difficulties in IADL
Number of subjects: 2006

Group type: EXPERIMENTAL
Intervention: Gender (women vs men)
Number of subjects: 2006

Group type: EXPERIMENTAL
Intervention: Employment status (dependants vs non-dependants)
Number of subjects: 2006

Group type: EXPERIMENTAL
Intervention: Living in a city vs rural area
Number of subjects: 2006
Study: 28615379

Group type: EXPERIMENTAL
Intervention: Lipid-based nutrient supplements (LNS-PL) containing 250 mug iodine, 20 g/d, 118 kcal
Number of subjects: 4011

Group type: COMPARATOR
Intervention: Iron and folic acid (IFA; 60 mg Fe/d + 400 mug folic acid/d)
Number of subjects: 4011
Study: 26095867

Group type: EXPERIMENTAL
Intervention: Bridging therapy with low‐molecular‐weight heparin (100 IU of dalteparin per kilogram of body weight) administered subcutaneously twice daily from 3 days before the procedure until 24 hours before the procedure and then for 5 to 10 days after the procedure.
Number of subjects: 1884

Group type: COMPARATOR
Intervention: No bridging therapy (placebo).
Number of subjects: 1884

Group type: EXPERIMENTAL
Intervention: Bridging therapy with low‐molecular‐weight heparin (100 IU of dalteparin per kilogram of body weight).
Number of subjects: 1884
Study: 23497506

Group type: EXPERIMENTAL
Intervention: Metabolic syndrome prevalence based on ATPIII criteria (update 2005)
Number of subjects: 912

Group type: EXPERIMENTAL
Intervention: Abdominal obesity prevalence
Number of subjects: 912

Group type: EXPERIMENTAL
Intervention: High triglyceride level prevalence
Number of subjects: 912

Group type: EXPERIMENTAL
Intervention: Low HDL prevalence
Number of subjects: 912

Group type: EXPERIMENTAL
Intervention: Hypertension prevalence
Number of subjects: 912

Group type: EXPERIMENTAL
Intervention: Abnormal fasting blood sugar prevalence
Number of subjects: 912

Group type: EXPERIMENTAL
Intervention: Age, BMI, sex differences in metabolic syndrome prevalence
Number of subjects: 912

Group type: EXPERIMENTAL
Intervention: Ethnicity, smoking, family history, marital status, education level, parity, previous history of GDM
Number of subjects: 912
Study: 21883122

Group type: EXPERIMENTAL
Intervention: i-gel
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Combitube
Number of subjects: 58

Group type: COMPARATOR
Intervention: Standard uniform
Number of subjects: 58

Group type: COMPARATOR
Intervention: CBRN-PPE
Number of subjects: 58
Study: 19124984

Group type: EXPERIMENTAL
Intervention: Tai Chi (TC)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Conventional structured exercise program
Number of subjects: 21
Study: 17446964

Group type: EXPERIMENTAL
Intervention: Cryptosporidium spp. infection in patients with gastroenteritis
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Giardia lamblia infection in patients with gastroenteritis
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Ascaris lumbricoides infection in patients with gastroenteritis
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Entamoeba histolytica infection in patients with gastroenteritis
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control group (healthy individuals)
Number of subjects: 104
Study: 15076258

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 11165220

Group type: EXPERIMENTAL
Intervention: Temporal covariance method using Gd-chelates contrast agent during myocardial perfusion imaging.
Number of subjects: 22

Group type: COMPARATOR
Intervention: Healthy volunteers (control group).
Number of subjects: 22
Study: 9779207

Group type: EXPERIMENTAL
Intervention: Sevoflurane 1.5%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sevoflurane 2.5%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sevoflurane 1.5% to 2.5%
Number of subjects: 0
Study: 8981711

Group type: EXPERIMENTAL
Intervention: Early photocoagulation
Number of subjects: 3711
Study: 2643592

Group type: EXPERIMENTAL
Intervention: Preoperative hyperthermia (HT) 2 treatments per week
Number of subjects: 17

Group type: COMPARATOR
Intervention: Preoperative hyperthermia (HT) 1 treatment per week
Number of subjects: 17
Study: 78155

Group type: EXPERIMENTAL
Intervention: Probenecid 2 g given 30 min before 300 mg of rifampicin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rifampicin 600 mg standard dose
Number of subjects: 0
Study: 31762155

Group type: EXPERIMENTAL
Intervention: Xenogeneic acellular dermal matrix (XADM)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Subepithelial connective tissue graft (CTG)
Number of subjects: 12
Study: 30911753

Group type: EXPERIMENTAL
Intervention: Continuous Grazing (CON)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Rotational Grazing (ROT)
Number of subjects: 12
Study: 27676630

Group type: EXPERIMENTAL
Intervention: Experiencing one to three stressful life events (SLEs)
Number of subjects: 518

Group type: EXPERIMENTAL
Intervention: Experiencing four to nine stressful life events (SLEs)
Number of subjects: 518

Group type: EXPERIMENTAL
Intervention: Each additional stressful life event experienced
Number of subjects: 518
Study: 26282640

Group type: EXPERIMENTAL
Intervention: Live music (LM) preoperatively with therapist-selected recorded music intraoperatively (n=69)
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Recorded music (RM) preoperatively with therapist-selected recorded music intraoperatively (n=70)
Number of subjects: 207

Group type: COMPARATOR
Intervention: Usual care (UC) preoperatively with noise-blocking earmuffs intraoperatively (n=68)
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Live music (LM)
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Recorded music (RM)
Number of subjects: 207

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 207
Study: 24052026

Group type: EXPERIMENTAL
Intervention: Robotic‐assisted gait training plus conventional physical therapy
Number of subjects: 42

Group type: COMPARATOR
Intervention: Conventional physical therapy
Number of subjects: 42

Group type: COMPARATOR
Intervention: Robotic‐assisted gait training dropout
Number of subjects: 42
Study: 22379908

Group type: EXPERIMENTAL
Intervention: Combined anesthesia with Propofol, Phentanil, and superficial cervical plexus block (SCPB)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Phentanil and Propofol
Number of subjects: 50
Study: 19929447

Group type: EXPERIMENTAL
Intervention: Eletriptan 40 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Eletriptan 80 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Eletriptan 40 mg and 80 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Eletriptan
Number of subjects: 0
Study: 16971319

Group type: EXPERIMENTAL
Intervention: Topical 1% sildenafil applied twice daily for 3 months
Number of subjects: 8
Study: 15374558

Group type: EXPERIMENTAL
Intervention: Dolasetron 12.5 mg IV
Number of subjects: 4587

Group type: EXPERIMENTAL
Intervention: Dolasetron 50 mg IV
Number of subjects: 4587

Group type: EXPERIMENTAL
Intervention: Dolasetron (various doses)
Number of subjects: 4587

Group type: COMPARATOR
Intervention: Ondansetron (comparator)
Number of subjects: 4587
Study: 11389118

Group type: EXPERIMENTAL
Intervention: Oral valaciclovir 1000 mg tds
Number of subjects: 15

Group type: COMPARATOR
Intervention: Intravenous aciclovir 5 mg/kg tds
Number of subjects: 15
Study: 9256846

Group type: EXPERIMENTAL
Intervention: Health service intervention trial
Number of subjects: 167
Study: 8252687

Group type: EXPERIMENTAL
Intervention: Intensive therapy (colestipol 10 g TID plus niacin 1 g QID or lovastatin 20 mg BID)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Conventional therapy (placebos or colestipol if LDL cholesterol was elevated)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Intensive therapy
Number of subjects: 29

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Asymptomatic patients
Number of subjects: 29
Study: 3556338

Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg at night
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study: 29784634

Group type: EXPERIMENTAL
Intervention: Touch Surgery app - chest tube insertion module
Number of subjects: 116

Group type: COMPARATOR
Intervention: Thoracocentesis module (control)
Number of subjects: 116
Study: 28733151

Group type: EXPERIMENTAL
Intervention: Chewing sugar-free gum for 1 hour (GC)
Number of subjects: 33

Group type: COMPARATOR
Intervention: No gum chewing (NG)
Number of subjects: 33
Study: 25911632

Group type: EXPERIMENTAL
Intervention: Younger males at 70 %MVC
Number of subjects: 34

Group type: COMPARATOR
Intervention: Younger females
Number of subjects: 34

Group type: COMPARATOR
Intervention: Older males
Number of subjects: 34

Group type: COMPARATOR
Intervention: Older females
Number of subjects: 34
Study: 23137823

Group type: EXPERIMENTAL
Intervention: Intralipid infusion
Number of subjects: 15

Group type: COMPARATOR
Intervention: Saline infusion (control)
Number of subjects: 15
Study: 21315217

Group type: EXPERIMENTAL
Intervention: n-3 polyunsaturated fatty acids (n-3PUFA)
Number of subjects: 566

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 566

Group type: EXPERIMENTAL
Intervention: n-3PUFA
Number of subjects: 566
Study: 19713693

Group type: EXPERIMENTAL
Intervention: mirtazapine or venlafaxine for 28 days
Number of subjects: 34
Study: 17062807

Group type: EXPERIMENTAL
Intervention: Active commuting to school (walking, biking, or skateboarding almost every day)
Number of subjects: 1083

Group type: EXPERIMENTAL
Intervention: Active commuting to school
Number of subjects: 1083

Group type: COMPARATOR
Intervention: Non-active commuting to school
Number of subjects: 1083
Study: 12616670

Group type: EXPERIMENTAL
Intervention: Delavirdine 400 mg tid with orange juice
Number of subjects: 21

Group type: COMPARATOR
Intervention: Delavirdine 400 mg tid with water
Number of subjects: 21
Study: 10634735

Group type: EXPERIMENTAL
Intervention: Penicillin V for seven days
Number of subjects: 561

Group type: EXPERIMENTAL
Intervention: Penicillin V for three days
Number of subjects: 561

Group type: COMPARATOR
Intervention: Placebo for seven days
Number of subjects: 561
Study: 9176538

Group type: EXPERIMENTAL
Intervention: Hypoxic gas mixture (Fio2 0.15)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Air (Fio2 0.21)
Number of subjects: 0
Study: 8385164

Group type: EXPERIMENTAL
Intervention: Medium viscosity WSDF mixture (psyllium, pectin, guar gum, locust bean gum)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Acacia gum
Number of subjects: 29
Study: 2908819

Group type: EXPERIMENTAL
Intervention: Atenolol (beta 1-selective blocker without agonistic activity)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Visacor (ICI 141 292) (beta 1-selective blocker with moderate beta 1-selective agonism)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Corwin (ICI 118 587) (beta 1-selective blocker with high beta 1-selective agonism)
Number of subjects: 3

Group type: COMPARATOR
Intervention: All three compounds during exercise-induced sympathetic activation
Number of subjects: 3
Study: 31904707

Group type: EXPERIMENTAL
Intervention: Positively Smoke Free (PSF)
Number of subjects: 450

Group type: COMPARATOR
Intervention: Brief advice to quit (Control)
Number of subjects: 450
Study: 28512699

Group type: EXPERIMENTAL
Intervention: 60-mg edoxaban tablet crushed and administered via a nasogastric tube
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 60-mg edoxaban tablet crushed and administered in apple puree
Number of subjects: 30

Group type: COMPARATOR
Intervention: 60-mg edoxaban tablet (whole)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: nasogastric tube suspension
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: apple puree
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: All treatment regimens
Number of subjects: 30
Study: 27599993

Group type: EXPERIMENTAL
Intervention: 6 months of heart rate based telemonitoring guidance
Number of subjects: 120

Group type: COMPARATOR
Intervention: traditional follow-up after cardiac rehabilitation
Number of subjects: 120
Study: 24815673

Group type: EXPERIMENTAL
Intervention: ziprasidone (40-160 mg/day)
Number of subjects: 106

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 106
Study: 22986377

Group type: EXPERIMENTAL
Intervention: Thalidomide
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 19836155

Group type: COMPARATOR
Intervention: 64-Gy CFRT
Number of subjects: 843

Group type: EXPERIMENTAL
Intervention: 74-Gy CFRT
Number of subjects: 843
Study: 18925526

Group type: EXPERIMENTAL
Intervention: Group 1: Needles in opposite directions with a distance of 5 cm or more
Number of subjects: 174

Group type: COMPARATOR
Intervention: Group 4: Unidirectional needles separated by a distance of less than 5 cm
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Group 5: Patients carrying a temporary venous catheter
Number of subjects: 174
Study: 16101604

Group type: EXPERIMENTAL
Intervention: Empowerment training for Chinese abused pregnant women
Number of subjects: 110

Group type: COMPARATOR
Intervention: Standard care for abused women
Number of subjects: 110
Study: 12419717

Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg and dexamethasone 8 mg (OD8 group)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg and dexamethasone 16 mg (OD16 group)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Saline (P group)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Ondansetron 4 mg (O group)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg and dexamethasone 2 mg (OD2 group)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg and dexamethasone 4 mg (OD4 group)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 180
Study: 11196122

Group type: EXPERIMENTAL
Intervention: Apraclonidine 1%
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Timolol 0.5%
Number of subjects: 12
Study: 8549927

Group type: EXPERIMENTAL
Intervention: Smoking (15 packages of cigarettes a year)
Number of subjects: 9844

Group type: EXPERIMENTAL
Intervention: More than five pregnancies
Number of subjects: 9844
Study: 1683818

Group type: EXPERIMENTAL
Intervention: E100 (100 mg esmolol)
Number of subjects: 548

Group type: EXPERIMENTAL
Intervention: E200 (200 mg esmolol)
Number of subjects: 548

Group type: COMPARATOR
Intervention: PLAC (placebo)
Number of subjects: 548
Study: 7121808

Group type: EXPERIMENTAL
Intervention: Iohexol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Urografin Meglumine
Number of subjects: 0
Study: 31288561

Group type: EXPERIMENTAL
Intervention: Newer-generation DES
Number of subjects: 10448

Group type: COMPARATOR
Intervention: Early-generation DES
Number of subjects: 10448

Group type: EXPERIMENTAL
Intervention: Noninsulin-dependent DM
Number of subjects: 10448

Group type: EXPERIMENTAL
Intervention: Insulin-dependent DM
Number of subjects: 10448

Group type: EXPERIMENTAL
Intervention: Definite or probable stent thrombosis
Number of subjects: 10448

Group type: EXPERIMENTAL
Intervention: Target lesion revascularization
Number of subjects: 10448
Study: 25641773

Group type: EXPERIMENTAL
Intervention: Geriatric consultative service (GCS)
Number of subjects: 415

Group type: COMPARATOR
Intervention: Control (no GCS)
Number of subjects: 415
Study: 25935943

Group type: EXPERIMENTAL
Intervention: Rizatriptan
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional therapy (paracetamol 500 mg + metoclopramide 10 mg + flunarizine 10 mg + alprazolam 0.5 mg)
Number of subjects: 0
Study: 22972771

Group type: COMPARATOR
Intervention: Stress Management (SM)
Number of subjects: 391

Group type: COMPARATOR
Intervention: Exercise (EX)
Number of subjects: 391

Group type: COMPARATOR
Intervention: Stress Management and Exercise (SMEX)
Number of subjects: 391

Group type: COMPARATOR
Intervention: Coping Confidence
Number of subjects: 391
Study: 19079814

Group type: EXPERIMENTAL
Intervention: TJ‐54 treatment (yokukansan) in period I
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: TJ‐54 treatment (yokukansan) in period II
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: TJ‐54 treatment in group A
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: TJ‐54 treatment in group B
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: TJ‐54 treatment
Number of subjects: 106

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 106
Study: 18085465

Group type: EXPERIMENTAL
Intervention: Olopatadine 0.2% ophthalmic solution (Pataday)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Olopatadine 0.1% ophthalmic solution (Patanol)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 16026692

Group type: EXPERIMENTAL
Intervention: Bolus 5-FU/leucovorin (LV) for 6 months
Number of subjects: 801

Group type: COMPARATOR
Intervention: Protracted venous infusion (PVI) 5-FU for 12 weeks
Number of subjects: 801

Group type: EXPERIMENTAL
Intervention: Both arms (Bolus 5-FU/LV and PVI 5-FU)
Number of subjects: 801

Group type: COMPARATOR
Intervention: PVI 5-FU
Number of subjects: 801
Study: 11920308

Group type: EXPERIMENTAL
Intervention: Oral ganciclovir for 8 weeks
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69